Author

Barbara Tolusso 1

1 Institute of Rheumatology, Fondazione Policlinico Universitario A. Gemel

Early Vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Elisa Gremese, Barbara Tolusso, Clara Di Mario, Alfredo Papa, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

HISTOLOGICAL FEATURES OF JOINT AND COLONIC INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH ANTI-TNFA

Stefano Alivernini, Daniela Pugliese, Barbara Tolusso, Luca Petricca, Laura Bui, Luisa Guidi, Gian Lodovico Rapaccini, Francesco Federico, Gianfranco Ferraccioli, Alessandro Armuzzi, Elisa Gremese

INFLIXIMAB LEVEL AND ANTI-DRUG ANTIBODY IN INFLAMMATORY BOWEL DISEASE PATIENTS LOSING RESPONSE: ASSAY AFTER OPTIMIZATION AND OUTCOME AT ONE YEAR.

Luisa Guidi, Manuela Marzo, Barbara Tolusso, Daniela Pugliese, Gianluca Andrisani, Carla Felice, Rosario Landi, Silvia Canestri, Elisa Gremese, Italo De Vitis, Alfredo Papa, Gian Lodovico Rapaccini, Alessandro Armuzzi

VEDOLIZUMAB TROUGH LEVELS DURING AND AFTER INDUCTION CORRELATE WITH CLINICAL AND ENDOSCOPIC OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Daniela Pugliese, Luisa Guidi, Tommaso Panici Tonucci, Virginia Solitano, Carla Felice, Giuseppe Privitera, Barbara Tolusso, Eugenia Onori, Lorenzo Bertani, Francesco Costa, Luigi Giovanni Papparella, Elisa Gremese, Alfredo Papa, Italo De Vitis, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Barbara Tolusso, Carla Felice, Alfredo Papa, Italo De Vitis, Elisa Gremese, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

Item 1 - 5 / 5
1